KAS
ABMD

Kestra Advisory Services’s Abiomed Inc ABMD Stock Holding History

Kestra Advisory Services’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,106
Closed -$517K – 2375
2022
Q3 		$517K Sell
2,106
-158
-7% -$42.7K 0.01% 1296
2022
Q2 		$560K Buy
2,264
+352
+18% +$95K 0.01% 1268
2022
Q1 		$633K Buy
+1,912
New +$589K 0.01% 1156

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Kestra Advisory Services's ABMD Position: Q4 2022 in Review

Kestra Advisory Services sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 2,106 shares — an estimated $517K sold.

Kestra Advisory Services first reported a position in ABMD in Q1 2022 and held it in 3 quarters. The position peaked at $633K in Q1 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Kestra Advisory Services reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Kestra Advisory Services sold 2,106 Abiomed Inc shares in Q4 2022, an estimated $517K.
  • Kestra Advisory Services first reported a position in Abiomed Inc in Q1 2022 and held it in 3 quarters.
  • Kestra Advisory Services's Abiomed Inc position peaked at $633K in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Kestra Advisory Services's 13F filing for Q4 2022, filed 31 Jan 2023.